|Day Low/High||75.84 / 77.15|
|52 Wk Low/High||53.22 / 78.47|
The prospect of a potential recession this year means investors must be more vigilant than ever in selecting stocks for their portfolio.
Recently poor sector performance is creating opportunity for long-term investors.
Plus, while market breadth stunk yesterday, it was on lower trading volume, which is an encouraging sign.
Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.
ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.
In this market environment, there is nothing wrong with a 'rinse, wash and repeat' trade.
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
Blue chip stock Bristol-Myers Squibb has a high dividend yield and an excellent pipeline.
As few seem interested in pre-holiday stock shopping, Monday shows extended indexes and names struggling to find support.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
I think these names will benefit from this theme, which I project will start to occur right after the Thanksgiving holiday this year.
J&J will be separating into two distinct firms, but not right away.
I tend to only use this strategy to a great extent when I have a negative or neutral view on the overall market.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?
* The attractiveness of Coinbase Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...
Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.
Let's look at the companies that can go up, and the ones that can't.